Formoterol 12 μg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: A multicenter, randomized, open-label, parallel-group study

Clinical Therapeutics

Volumn 25, Issue 7, 2003, Pages 2022-2036

  Brambilla, Christian ^a   Le Gros, Vincent ^b   Bourdeix, Isabelle ^b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b NOVARTIS PHARMA K K   (Japan)

Author keywords

Aerolizer; Asthma; Formoterol; Inhaled corticosteroids; Salbutamol; Salmeterol

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL FUMARATE; LONG ACTING DRUG; SALBUTAMOL; SALMETEROL XINAFOATE; BRONCHODILATING AGENT; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; FORMOTEROL; SALMETEROL;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHMA; BRONCHITIS; CLINICAL TRIAL; COLD SENSATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRY POWDER; EDEMA; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MOUTH DISEASE; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; OPEN STUDY; PEAK EXPIRATORY FLOW; POWDER INHALER; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SINGLE DRUG DOSE; SWEATING; SYMPTOM; TACHYCARDIA; TREATMENT OUTCOME; TREMOR; VERTIGO; XEROSTOMIA; COMPARATIVE STUDY; DRUG COMBINATION; MIDDLE AGED; NEBULIZER; POWDER;

ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; POWDERS;

EID: 0043204374     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80202-3     Document Type: Article

References (34)

1. Beasley R, Masoli M. Evidence that current therapeutic goals have not been met in asthma. Prim Care Respir J. 2002;11(Suppl 1):S3-S6.
2. NHLBI/WHO Workshop Report Global Strategy for Asthma Management and Prevention. Update 2002. Bethesda, Md: National Institutes of Health. NIH Publication no. 02-3659.
3. Global Initiative for Asthma: Pochet Guide for Asthma Management and Prevention. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; 1998. Publication no. 96-3658B.
4. British Thoracic Society. Guidelines on the management of asthma. Thorax. 1997;52:S1-S21.
5. Greening AP, Ind PW, Northfield M, Shaw G, for the Allen & Hanburys Limited UK Study Group. Added salmeterol versus higher-dose corticosteroids in asthma patients with symptoms on existing inhaled corticosteroid. Lancet. 1994;344:219-224.
6. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996;153:1481-1488.
7. Pauwels RA, Lofdahl CG, Postma DS, et al, for the Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337:1405-1411.
8. Kelsen SG, Church NL, Gillman SA, et al. Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: A randomized clinical trial. J Asthma. 1999;36:703-715.
9. van Noord JA, Schreurs AJ, Mol SJ, Mulder PG. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax. 1999;54:207-212.
10. Vermetten FA, Boermans AJ, Luiten WD, et al. Comparison of salmeterol with beclomethasone in adult patients with mild persistent asthma who are already on low-dose inhaled steroids. J Asthma. 1999;36:97-106.
11. Bouros D, Bachlitzanakis N, Kottakis J, et al. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. Eur Respir J. 1999;14:627-632.
12. Condemi JJ, Goldstein S, Kalberg C, et al, for the Salmeterol Study Group. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Ann Allergy Asthma Immunol. 1999;82:383-389.
13. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ. 2000;320:1368-1373.
14. van Noord JA, Smeets JJ, Raaijmakers JA, et al. Salmeterol versus formoterol in patients with moderately severe asthma: Onset and duration of action. Eur Respir J. 1996;9:1684-1688.
15. Palmqvist M, Persson G, Lazer L, et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: Onset of action, duration of effect and potency. Eur Respir J. 1997;10:2484-2489.
16. Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J. 1999;13:988-992.
17. Naline E, Zhang Y, Qian Y, et al. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur Respir J. 1994;7:914-920.
18. Kallstrom BL, Sjoberg J, Waldeck B. The interaction between salmeterol and beta 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro. Br J Pharmacol. 1994;113:687-692.
19. Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med. 1999;160:244-249.
20. 2 adrenoceptor agonists: Interactions in human contracted bronchi. Eur Respir J. 1998;11:583-588.
21. Molimard M, Bourcereau J, Le Gros V, et al. Comparison between formoterol 12 microg b.i.d, and on-demand salbutamol in moderate persistent asthma. Respir Med. 2001;95:64-70.
22. FitzGerald JM, Chapman KR, Della Cioppa G, et al, for the Canadian FO/OD1 Study Group. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. J Allergy Clin Immunol. 1999;103:427-435.
23. Bensch G, Lapidus RJ, Levine BE, et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol. 2001;86:19-27.
24. Jeppsson AB, Kallstrom BL, Waldeck B. Studies on the interaction between formoterol and salmeterol in guinea-pig trachea in vitro. Pharmacol Toxicol. 1992;71:272-277.
25. Hanania NA, Sharafkhaneh A, Barber R, Dickey BF. Beta-agonist intrinsic efficacy: Measurement and clinical significance. Am J Respir Crit Care Med. 2002;165:1353-1358.
26. Anderson GP. Formoterol: Pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci. 1993;52:2145-2160.
27. Ulrik CS, Kok-Jensen A. Different bronchodilating effect of salmeterol and formoterol in an adult asthmatic. Eur Respir J. 1994;7:1003-1005.
28. Noppen M, Vinken W. Bronchodilating effect of formoterol but not of salmeterol in two asthmatic patients. Respiration. 2000;67:112-113.
29. Kottakis J, Wood R, Le Gros V, Della Cioppa G. Clinical efficacy with formoterol in the absence of a response to salmeterol: A review. Int J Clin Pract. 2001;55:476-479.
30. Green SA, Spasoff AP, Coleman RA, et al. Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. J Biol Chem. 1996;271:24029-24035.
31. Green SA, Rathz DA, Schuster AJ, Liggett SB. The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Eur J Pharmacol. 2001;421:141-147.
32. Vervloet D, Ekstrom T, Pela R, et al. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Respir Med. 1998;92:836-842.
33. Clauzel AM, Molimard M, Le Gros V, et al. Use of formoterol dry powder administered for three months via a single-dose inhaler in 1,380 asthmatic patients. J Investig Allergol Clin Immunol. 1998;8:265-270.
34. Condemi JJ. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: A multicenter, randomized, open-label trial. Clin Ther. 2001;23:1529-1541.